Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eptifibatide
Drug ID BADD_D00792
Description Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Indications and Usage For treatment of myocardial infarction and acute coronary syndrome.
Marketing Status Prescription; Discontinued
ATC Code B01AC16
DrugBank ID DB00063
KEGG ID D06888
MeSH ID D000077542
PubChem ID 448812
TTD Drug ID D09ZIO
NDC Product Code 67457-631; 32861-0002; 16729-260; 36974-0068; 72078-026; 70436-026; 14403-0007; 70121-1003; 52958-402; 55150-218; 55150-220; 70436-162; 68225-005; 70436-163; 52958-128; 0338-9559; 16729-259; 14335-070; 70121-1002; 14335-071; 17478-902; 55150-219; 41524-0002; 52958-001; 25021-409; 62756-500; 25021-408; 0338-9558; 68225-006; 70436-027; 72078-025; 67457-630; 17478-903; 70860-303; 72078-027; 67457-629
Synonyms Eptifibatide | Epifibratide | Epifibatide | 7H-Pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)- | Integrilin | Integrelin
Chemical Information
Molecular Formula C35H49N11O9S2
CAS Registry Number 188627-80-7
SMILES C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC (=O)O)CCCCN=C(N)N)C(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Surgical and medical proceduresIntegrin beta-3P05106T2645710195947; 11447076; 11151063; 11425767
Surgical and medical proceduresIntegrin alpha-IIbP08514Not Available10195947; 11447076; 11151063; 11425767
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioplasty25.03.01.005--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Body temperature increased13.15.01.001--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.004--Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.005--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Coronary artery bypass25.03.03.003--Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery occlusion02.02.01.006; 24.04.04.013--Not Available
Dermatitis23.03.04.002--Not Available
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Epistaxis22.04.03.001; 24.07.01.005--
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Haemorrhagic stroke24.07.04.014; 17.08.01.011--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages